A once-daily lopinavir/ritonavir-based regimen is noninferior to twice-daily dosing and results in similar safety and tolerability in antiretroviral-naive subjects through 48 weeks.
about
Comparison of once-daily versus twice-daily combination antiretroviral therapy in treatment-naive patients: results of AIDS clinical trials group (ACTG) A5073, a 48-week randomized controlled trialFrench 2013 guidelines for antiretroviral therapy of HIV-1 infection in adults.Pharmacokinetics of lopinavir-ritonavir with and without nonnucleoside reverse transcriptase inhibitors in Ugandan HIV-infected adults.Protease Inhibitors for Patients With HIV-1 Infection: A Comparative Overview.Sex-based outcomes of darunavir-ritonavir therapy: a single-group trial.Low lopinavir plasma or hair concentrations explain second-line protease inhibitor failures in a resource-limited settingRecruitment and retention of diverse populations in antiretroviral clinical trials: practical applications from the gender, race and clinical experience study.Boosted lopinavir- versus boosted atazanavir-containing regimens and immunologic, virologic, and clinical outcomes: a prospective study of HIV-infected individuals in high-income countries.CYP3A4-mediated lopinavir bioactivation and its inhibition by ritonavir.Once vs. twice-daily lopinavir/ritonavir in HIV-1-infected children.Renal function with use of a tenofovir-containing initial antiretroviral regimenA randomized controlled trial to assess safety, tolerability, and antepartum viral load with increased lopinavir/ritonavir dosage in pregnancyLower pill burden and once-daily antiretroviral treatment regimens for HIV infection: A meta-analysis of randomized controlled trials.Ritonavir-boosted protease inhibitors in HIV therapy.Examination of noninferiority, safety, and tolerability of lopinavir/ritonavir and raltegravir compared with lopinavir/ritonavir and tenofovir/ emtricitabine in antiretroviral-naïve subjects: the progress study, 48-week results.Discontinuation of tenofovir disoproxil fumarate for presumed renal adverse events in treatment-naïve HIV-1 patients: meta-analysis of randomized clinical studies.Formulation preference, tolerability and quality of life assessment following a switch from lopinavir/ritonavir soft gel capsule to tablet in human immunodeficiency virus-infected patients.Treatment outcomes and plasma level of ritonavir-boosted lopinavir monotherapy among HIV-infected patients who had NRTI and NNRTI failure.Once-daily antiretroviral therapy among treatment-experienced Muslim patients fasting for the month of Ramadan.Diarrhea associated with lopinavir/ritonavir-based therapy: results of a meta-analysis of 1469 HIV-1-infected participants.Meta-analysis of the safety, tolerability, and efficacy of lopinavir/ritonavir-containing antiretroviral therapy in HIV-1-infected women.Randomized controlled trial of the tolerability and completion of maraviroc compared with Kaletra® in combination with Truvada® for HIV post-exposure prophylaxis (MiPEP Trial).HIV protease inhibitors: present and futureAssessing the Efficacy of Lopinavir/Ritonavir-Based Preferred and Alternative Second-Line Regimens in HIV-Infected Patients: A Meta-Analysis of Key Evidence to Support WHO Recommendations
P2860
Q33708071-1CAE8C26-A38F-41E9-A9B2-22DC6C7AAAD8Q33775397-58234EF2-06F7-405F-A612-29BAEF3B6CE3Q33962762-D5FB0122-0ED8-4491-957D-BA544B638DEDQ34631149-F687F9C1-0C07-4AE5-BFB4-71B73ED53057Q34664004-9D2847E9-1765-4A34-8CA1-579D0038780BQ34778123-33B6CF12-9E1E-4772-B0A7-E28FA4CDD69AQ35088773-5AA1C9AF-5F4C-4CB1-8E3D-7D903F537434Q35539510-B9B86FF0-4C93-4AB9-9BA7-D7073F09ED25Q35647173-533943D1-2B05-4B01-9601-174C47FC9657Q36282719-5C4937B1-197D-4A8A-A4A7-B0F08D76DCDEQ37215065-6562190E-DDF7-4100-A30F-A0452F9600ACQ37286950-9CD8DB2C-FDF3-4A23-BD46-857EEE31B391Q37696578-6910FEF0-FEFF-43D4-A56A-B98E61B259A0Q37866319-31366440-345E-4F69-A44C-486F82226E93Q39394704-12F4258A-7794-4B23-BE85-9B366E633520Q41643193-937A07E7-08F7-4F41-8FC3-34D5BD0D0006Q42933928-1D483D3A-978D-4B24-84C8-4EE43B8DF89FQ42938439-8B48D273-84F2-4F34-AB37-7B618FB1711DQ44636815-33AD8324-F641-4E16-ADA9-4F931111D2ECQ44641855-3D8D20B2-9F85-493C-A371-41641FABE537Q46173618-6223BA93-A0B2-40E3-969A-4A1AED2DA2F8Q47830535-CDE7152E-353A-489D-BDEF-1584FB125900Q58290794-A3EFD44A-D100-4E04-B5AC-9546B4B53929Q58780819-23C72FF7-177E-49EF-A681-494A5AED192E
P2860
A once-daily lopinavir/ritonavir-based regimen is noninferior to twice-daily dosing and results in similar safety and tolerability in antiretroviral-naive subjects through 48 weeks.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
A once-daily lopinavir/ritonav ...... ive subjects through 48 weeks.
@en
A once-daily lopinavir/ritonav ...... ive subjects through 48 weeks.
@nl
type
label
A once-daily lopinavir/ritonav ...... ive subjects through 48 weeks.
@en
A once-daily lopinavir/ritonav ...... ive subjects through 48 weeks.
@nl
prefLabel
A once-daily lopinavir/ritonav ...... ive subjects through 48 weeks.
@en
A once-daily lopinavir/ritonav ...... ive subjects through 48 weeks.
@nl
P2093
P1476
A once-daily lopinavir/ritonav ...... ive subjects through 48 weeks.
@en
P2093
Barbara A da Silva
Barry Bernstein
Christian Naylor
Daniel E Cohen
Daniel Podzamczer
Joseph Gathe
Linda Fredrick
Mona R Loutfy
Rafael Rubio
Sara Gibbs
P304
P356
10.1097/QAI.0B013E31819C2937
P407
P577
2009-04-01T00:00:00Z